Ajay Vikram Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ajay Vikram Singh has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Manish Khare
Department of Applied Sciences, Maharashtra Academy of Engineering, Alandi (D), Pune, Maharashtra, India
1 shared publication Paolo Zamboni
Centre for Vascular Disease, University of Ferrara, 41100 Ferrara, Italy
1 shared publicationW. N. Gade
Department of Biotechnology, University of Pune, Ganeshkhind Road, Pune 411 007, India
1 shared publication
Latest Publications
- Open Access
- 30 December 2012
- Published by Hindawi Limited in Autoimmune Diseases
- Vol. 2012, 1-12
Theranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective
Multiple Sclerosis is a multifactorial disease with several pathogenic mechanisms and pathways. Successful MS management and medical care requires early accurate diagnosis along with specific treatment protocols based upon multifunctional nanotechnology approach. This paper highlights advances in nanotechnology that have enabled the clinician to target the brain and CNS in patient with multiple sclerosis with nanoparticles having therapeutic and imaging components. The multipartite theranostic (thera(py) + (diag)nostics) approach puts forth strong implications for medical care and cure in MS. The current nanotheranostics utilize tamed drug vehicles and contain cargo, targeting ligands, and imaging labels for delivery to specific tissues, cells, or subcellular components. A brief overview of nonsurgical nanorepair advances as future perspective is also described. Considering the potential inflammatory triggers in MS pathogenesis, a multifunctional nanotechnology approach will be needed for the prognosis.
- 30 December 2012
- Published by Hindawi Limited in Autoimmune Diseases
- Vol. 2012, 1-12
Open AccessTheranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective
Multiple Sclerosis is a multifactorial disease with several pathogenic mechanisms and pathways. Successful MS management and medical care requires early accurate diagnosis along with specific treatment protocols based upon multifunctional nanotechnology approach. This paper highlights advances in nanotechnology that have enabled the clinician to target the brain and CNS in patient with multiple sclerosis with nanoparticles having therapeutic and imaging components. The multipartite theranostic (thera(py) + (diag)nostics) approach puts forth strong implications for medical care and cure in MS. The current nanotheranostics utilize tamed drug vehicles and contain cargo, targeting ligands, and imaging labels for delivery to specific tissues, cells, or subcellular components. A brief overview of nonsurgical nanorepair advances as future perspective is also described. Considering the potential inflammatory triggers in MS pathogenesis, a multifunctional nanotechnology approach will be needed for the prognosis.